To include your compound in the COVID-19 Resource Center, submit it here.

Intercell, Vivalis deal

Vivalis will merge with infectious disease company Intercell in a stock deal that values Intercell at about €132.5 million ($174.4 million). The combined company, which will be a public company named Valneva SE, will also raise €40 million ($52.6 million) in a fully committed rights issue following the close of the merger, which is expected in May 2013.

Read the full 583 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE